Protagonist Therapeutics (PGF) Price & Analysis

1 Followers

PGF Stock Chart & Stats

€75.00

€0.00(0.00%)

At close: Jul 29 4:00 PM EDT

€75.00

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€43.40 - €81.00

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€7.62B

Enterprise Value€6.89K

Total Cash (Recent Filing)€782.58M

Total Debt (Recent Filing)€9.22M

Price to Earnings (P/E)―

Beta0.39

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.22

Shares Outstanding64,311,370

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.29

Price to Book (P/B)9.03

Price to Sales (P/S)120.66

P/FCF Ratio99.01

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€128.06

Price Target Upside70.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)3.71

Revenue Forecast (FY)€460.16M

Bulls Say, Bears Say

Bulls Say

Balance-sheet StrengthA very low leverage profile and large equity base provide durable financial flexibility to fund R&D, support commercialization, and absorb clinical setbacks without urgent refinancing. This reduces bankruptcy and interest-rate risk and preserves strategic optionality over the next several quarters.

Improved Cash GenerationMeaningful positive operating and free cash flow in the latest TTM indicate the company can fund near-term operations and development from internal cash if maintained. Sustained cash generation lowers reliance on dilutive financing and supports continued investment in commercialization and pipeline activities.

Commercial Milestone And Partnership ProceedsFDA approval and first commercial sales of ICOTYDE plus the $50M milestone and $200M rusfertide payment are structural: they convert clinical achievement into cash, de-risk the business, enhance runway, and create potential recurring royalty streams under partnerships.

Bears Say

Earnings And Revenue VolatilitySharp swings from large prior losses to recent profit reflect lumpy revenue recognition and one-off items common in biotech. This episodic performance makes cash flow and earnings less predictable, complicates capital allocation, and increases execution risk if milestone-driven inflows do not recur.

Dependence On Milestone/collaboration RevenueA business model reliant on upfront, milestone, and partner-funded R&D creates structurally uncertain revenue streams. Without a scaled commercial franchise, revenue visibility remains contingent on third-party decisions and regulatory timing, limiting sustainable organic revenue predictability.

Share-based Compensation / Dilution RiskAdoption of a broad equity incentive plan provides a recurring mechanism for share issuance to retain talent and align incentives. Over time, significant grant activity can increase share count, diluting per-share metrics and potentially offsetting improvements in cash generation unless managed conservatively.

Protagonist Therapeutics News

Protagonist Therapeutics price target raised to $175 from $130 at Citi

Citi analyst Geoff Meacham raised the firm’s price target on Protagonist Therapeutics (PTGX) to $175 from $130 and...

11h ago

PTGX

Protagonist Therapeutics price target raised to $173 from $116 at Clear Street

Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $173 from $116...

11h ago

PTGX

Protagonist Therapeutics price target raised to $153 from $151 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $153 from $151 and keeps an Overweight...

11h ago

PTGX

Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93

Reports Q2 revenue $213.48M, consensus $223.17M. “The second quarter of 2026 marked a defining growth phase for Protagonist...

21h ago

PTGX

Protagonist Therapeutics price target raised to $165 from $137 at Citizens

Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $165 from $137 and keeps an Outperform...

20d ago

PTGX

Protagonist Therapeutics price target raised to $151 from $119 at Barclays

Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $151 from $119 and keeps an Overweight...

23d ago

PTGX

Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval

Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Protagonist Therapeutics. The associated price target...

11h ago

PTGX

Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175

Citi analyst Geoff Meacham maintained a Buy rating on Protagonist Therapeutics today and set a price target of...

11h ago

PTGX

Protagonist Therapeutics Highlights ICOTYDE Launch and Rusfertide Deal

Protagonist Therapeutics ( ($PTGX) ) has provided an announcement. On August 5, 2026, Protagonist reported second-quarter 2026 results...

1d ago

PTGX

PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications

Protagonist Therapeutics Inc ($PTGX) announced an update on their ongoing clinical study. Protagonist Therapeutics, Inc. (PTGX) has completed...

1d ago

PTGX

Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating

Tara Bancroft, an analyst from TD Cowen, maintained the Buy rating on Protagonist Therapeutics. The associated price target...

16d ago

PTGX

Protagonist Therapeutics price target raised to $145 from $121 at Truist

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $145 from $121 and keeps a Buy...

1M ago

JNJ

PTGX

Protagonist Therapeutics Stockholders Approve Directors and Incentive Plan

Protagonist Therapeutics ( ($PTGX) ) has shared an announcement. At its recent Annual Meeting, Protagonist Therapeutics’ stockholders elected...

2M ago

PTGX

Protagonist Therapeutics price target raised to $130 from $125 at Citi

Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy...

3M ago

PTGX

PGF FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?

Protagonist Therapeutics lowest stock price was €43.40 and its highest was €81.00 in the past 12 months.

What is Protagonist Therapeutics’s market cap?

Protagonist Therapeutics’s market cap is €7.62B.

When is Protagonist Therapeutics’s upcoming earnings report date?

Protagonist Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 91 days.

How were Protagonist Therapeutics’s earnings last quarter?

Currently, no data Available

Is Protagonist Therapeutics overvalued?

According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Protagonist Therapeutics pay dividends?

Protagonist Therapeutics does not currently pay dividends.

What is Protagonist Therapeutics’s EPS estimate?

Protagonist Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Protagonist Therapeutics have?

Protagonist Therapeutics has 64,311,370 shares outstanding.

What happened to Protagonist Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Protagonist Therapeutics?

Currently, no hedge funds are holding shares in DE:PGF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Protagonist Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-6.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Protagonist Therapeutics (PGF) Earnings & Revenues

Historic Earnings Reports

PGF Stock 12 Month Forecast

Average Price Target

€128.06

▲(70.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"45":"€45","152":"€152","71.75":"€71.8","98.5":"€98.5","125.25":"€125.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":151.42691725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€151.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128.06390715999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€128.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.1826337,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€95.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[45,71.75,98.5,125.25,152],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,80.87899363461538,86.75798726923077,92.63698090384615,98.51597453846153,104.39496817307692,110.2739618076923,116.1529554423077,122.03194907692307,127.91094271153847,133.78993634615384,139.66892998076924,145.5479236153846,{"y":151.42691725,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,79.0818390123077,83.16367802461538,87.24551703692308,91.32735604923076,95.40919506153845,99.49103407384615,103.57287308615383,107.65471209846153,111.73655111076923,115.81839012307691,119.9002291353846,123.9820681476923,{"y":128.06390715999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75,76.55251028461538,78.10502056923077,79.65753085384615,81.21004113846153,82.76255142307693,84.31506170769231,85.86757199230769,87.42008227692307,88.97259256153846,90.52510284615384,92.07761313076924,93.63012341538462,{"y":95.1826337,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.5,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >